Drug Trial Radar · NCT07071441
Indomethacin vs Diclofenac for Preventing PEP
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
4,050
Planned (sponsor's estimate)
Start
Jun 1, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Air Force Military Medical University, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 17, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Preprocedural administration of rectal non-steroidal anti-inflammatory drugs (NSAIDs) was demonstrated to be an effective and convenient strategy for post-ERCP pancreatitis (PEP). Furthermore, several meta-analyses found that only 100mg indomethacin and diclofenac could effectively reduce PEP. Therefore, updated international clinical practice guidelines uniformly recommended administration of 100mg indomethacin or diclofenac in patients without contradictions. However, it was unclear which one of the two drug is more superior. A recent meta-analysis suggested 100mg rectal diclofenac was more efficacious than same-dose rectal indomethacin in PEP prevention (relative risk (RR) 0·59, 95% confidence intervals (CI) 0·40-0·89). Based on the results, we conducted a multicenter, double-blind, control trial to investigate whether 100mg diclofenac is superior than same-dose indomethacin. This trial planned to enroll 3612 patients in total. However, in the first interim analysis, PEP occurred in 53 patients (8.8%) of 600 patients allocated to diclofenac group and 37 patients (6.1%) of 604 patients allocated to indomethacin group (relative risk (RR) 1.44; 95% confidence interval (CI) 0.96-2.16, p=0.074). Thus, the trial was stopped according to the futility rule of conditional power. However, it was worth noticing that PEP tended to be higher in diclofenac group than that in indomethacin group. A sample size of 1204 was under power to draw the conclusion of significantly lower PEP rate in indomethacin group and thus a new trial with larger sample size of sufficient power is predicted to prove the superiority of indomethacin over diclofenac. Here we conducted a multicenter, randomized, double-blind trial to investigate whether 100mg indomethacin is superior to 100mg diclofenac in preventing PEP.
Conditions
- ERCP
- Pancreatitis
- Non-steroidal Anti-inflammatory (NSAID)
- Indomethacin
- Diclofenac
Interventions
Indomethacin 100 MGDrug
All patients without contraindications should receive 100mg rectal indomethacin within 30mins before ERCP procedure
Diclofenac 100mgDrug
All patients without contraindications should receive 100mg rectal diclofenac within 30mins before ERCP procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of post-ERCP PancreatitisTime frame: 30 days
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
The first medical center, Chinese PLA General Hospital
Beijing, Beijing Municipality, China · Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Department of Gastroenterology, Hongai Hospital
Xiamen, Fujian, China · Recruiting
Harbin Medical University Affiliated Fourth Hospital
Harbin, Heilongjiang, China · Recruiting
Zhaolei181220@163.Com
Harbin, Heilongjiang, China · Recruiting
Huaihe Hospital of Henan University
Kaifeng, Hennan, China · Recruiting
Renmin hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Jilin Miniciple People'S Hospital
Jilin City, Jilin, China · Recruiting
Qinghai University Affiliated Hospital
Xining, Qinghai, China · Recruiting
986 Hospital of Xijing Hospital
Xi'an, Shaanxi, China · Recruiting
Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Recruiting
Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, China · Recruiting
Shandong Provincial Third Hospital
Jinan, Shandong, China · Not yet recruiting
The 960th Hospital of the PLA
Jinan, Shandong, China · Recruiting
Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Affiliated Hangzhou First People's Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
the First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
the second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.